Philip J. Meacham

Philip J. Meacham

Auto-generated profile, based on publicly available information

Philip J. Meacham

Deloitte Consulting LLP, Arlington, VA 22209, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2018 in Leukemia Research
Verified
Journal Article
Closed access
WAWilliam J. Archibald
William J. Archibald
PMPhilip J. Meacham
Philip J. Meacham
AWAnnaLynn M. Williams
AnnaLynn M. Williams
ABAndrea M. Baran
Andrea M. Baran
AVAdrienne I. Victor
Adrienne I. Victor
CZClive S. Zent
Clive S. Zent

1 March 2017 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
BHBradley D. Hunter
Bradley D. Hunter
MHMegan Herr
Megan Herr
PMPhilip J. Meacham
Philip J. Meacham
FBFerdous Barlaskar
Ferdous Barlaskar
AEAndrew G. Evans
Andrew G. Evans
CCCarla Casulo
Carla Casulo

29 October 2024 in Antibiotics
Verified
Journal Article
Open access
PDF file
ARAllison Ross
Allison Ross
PMPhilip J. Meacham
Philip J. Meacham
JWJohn Paul Waswa
John Paul Waswa
Mohan P. JoshiMohan P. Joshi
Mohan P. Joshi
THTamara Hafner
Tamara Hafner
FKFreddy Kitutu
Freddy Kitutu
Background/Objectives: Antimicrobial resistance (AMR) is a global public health concern exacerbated by inappropriate antimicrobial prescribing practices, particularly in low-resource settings such as Uganda. The research aimed to develop a culturally sensitive behavioral intervention, leveraging a “nudge” strategy, to improve healthcare provider adherence to the 2016 Uganda Clinical Guidelines (UCG 2016) in five Ugandan hospitals. This intervention formed part of broader antimicrobial stewardship initiatives led by the United States Agency for International Development Medicines, Technologies, and Pharmaceutical Services Program. Methods: This study employed a mixed-methods approach, combining formative research and behavioral intervention. Guided by the Deloitte Behavioral Insights Framework, the research team conducted key informant interviews to identify prescribing barriers and motivators and developed three suitable behavioral interventions: perceived monitoring, ward leaderboards, and educational workshops. The study evaluated the interventions’ impact through point prevalence surveys (PPS), using the World Health Organization PPS methodology at three stages: pre-intervention, immediate post-intervention, and one-month post-intervention. Results: Key behavioral themes across individual, social, environmental, and organizational elements informed the intervention design and implementation. The behavioral intervention package increased antimicrobial prescription compliance with the UCG 2016 from 27% at baseline to 50% immediately post-intervention, though these effects diminished at one-month post-intervention. Conclusions: Our study addresses an existing gap in behavioral nudges-based operational research on antimicrobial prescribing in low- and middle-income countries. These results showed an immediate improvement in adherence to the UCG 2016 among healthcare providers in Ugandan hospitals, though the effect was attenuated at one-month follow-up. Despite the attenuation, behavior change presents a feasible, cost-effective, and sustainable approach to improving antimicrobial prescribing practices and addressing AMR.